Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on novel cancer therapies that target nuclear export dysregulation. Its lead product, XPOVIO (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor approved in the U.S. in multiple oncology indications and in various indications across more than 50 ex-U.S. territories and countries, according to company statements.
This news page aggregates company-issued updates and market disclosures related to Karyopharm. Readers can follow announcements on XPOVIO commercial performance, such as reported U.S. net product revenue and trends in license and royalty revenue from international partners, as described in the company’s earnings releases. The feed also covers progress in Karyopharm’s clinical pipeline, including multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL).
Recent news has highlighted key milestones in late-stage development, including completion of enrollment in the Phase 3 SENTRY trial (XPORT-MF-034) in myelofibrosis and ongoing enrollment in the global Phase 3 XPORT-EC-042 trial in TP53 wild-type advanced or recurrent endometrial cancer. Company releases also describe Phase 2 data in heavily pretreated myelofibrosis patients and the design of additional studies such as SENTRY-2 and XPORT-MM-031 in multiple myeloma.
In addition to clinical and commercial updates, Karyopharm’s news includes financial results, preliminary revenue disclosures, strategic financing transactions involving term loans and convertible notes, and inducement equity awards granted under its inducement stock incentive plan. Investors and observers can use this page to review the company’s own descriptions of its operational progress, financing activities and anticipated clinical catalysts as reported in press releases and referenced in SEC filings.
Karyopharm Therapeutics (Nasdaq: KPTI) has completed enrollment in its Phase 3 SENTRY trial, evaluating selinexor in combination with ruxolitinib for JAKi-naïve myelofibrosis patients. The trial enrolled 353 patients with top-line results expected in March 2026.
The study aims to assess if selinexor plus ruxolitinib could become the first approved combination therapy for myelofibrosis. The trial's co-primary endpoints include spleen volume response rate ≥35% at week 24 and the average change in absolute total symptom score over 24 weeks versus baseline. Patients were randomized 2-to-1 to receive either 60mg weekly selinexor with ruxolitinib or placebo with ruxolitinib.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 466 restricted stock units (RSUs) to two newly-hired employees as of August 31, 2025. The RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan.
The RSUs will vest over three years, with 33 1/3% vesting annually. Additionally, the RSUs include acceleration provisions in case of a change in control event followed by qualifying employment termination.
Karyopharm Therapeutics (Nasdaq: KPTI) reported Q2 2025 financial results with total revenue of $37.9 million, including U.S. XPOVIO net product revenue of $29.7 million, up 6% year-over-year. The company reaffirmed its full-year 2025 total revenue guidance of $140-155 million while updating U.S. XPOVIO revenue guidance to $110-120 million.
Key developments include the imminent completion of patient screening for the Phase 3 SENTRY trial in myelofibrosis, with top-line results expected in March 2026. However, the company faces financial challenges with $52.0 million in cash as of June 30, 2025, down from $109.1 million at year-end 2024. Karyopharm is actively exploring financing transactions and strategic alternatives to extend its cash runway beyond the October 2025 maturity of its convertible notes.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025.
The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day. Investors can access the call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). A live webcast with accompanying slides will be available on the company's investor relations website.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 333 restricted stock units (RSUs) to one newly-hired employee as of July 31, 2025. The RSUs will vest over three years, with 33 1/3% vesting annually on the grant date anniversary.
The grant was made under the company's 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). The RSUs include accelerated vesting provisions in case of a change in control event followed by qualifying employment termination.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has announced the granting of 666 restricted stock units (RSUs) to two newly-hired employees as of June 30, 2025.
The RSU awards, granted under the Company's 2022 Inducement Stock Incentive Plan, will vest over three years, with 33 1/3% vesting annually. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). Additionally, the RSUs include provisions for immediate full vesting in case of employment termination under specific conditions following a change in control event.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The company's senior management team will engage in a fireside chat on Wednesday, May 21 at 10:00 a.m. ET in New York. Investors and interested parties can access a live webcast of the presentation through the company's investor relations website, with a replay available after the event.
Karyopharm Therapeutics (KPTI) will present new data on selinexor in treating myelofibrosis at the 2025 EHA Annual Meeting. The Phase 2 XPORT-MF-035 trial results showed promising outcomes in hard-to-treat patients:
- 67% of selinexor-treated patients achieved ≥25% spleen volume reduction vs 38% in physician's choice (PC) group - 33% achieved ≥35% spleen volume reduction vs 13% in PC group - Higher mean hemoglobin levels and lower transfusion rates - Greater reductions in key cytokines (IL-6, IL-8, TNFa, hepcidin)
The trial involved 24 patients (12 per arm), with 6 crossing over from PC to selinexor. Common side effects included decreased weight (50%), anemia (25%), and nausea (33%). Notably, no treatment discontinuations occurred in the selinexor arm due to adverse events.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
